Cytokinetics CEO Robert Blum: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
This article was originally published in The Pink Sheet Daily
Executive Summary
Chief exec sits down with “The Pink Sheet” DAILY at BIO Investor Forum to discuss lead candidates in oncology and heart failure, and partnering with big pharma.
You may also be interested in...
Cytokinetics CEO Robert Blum: An Interview With “The Pink Sheet” DAILY (Part 2 Of 2)
In the second part of the interview at the BIO Investor forum, CEO Robert Blum discusses Cytokinetics’ deal with Amgen and long-range commercialization goals.
Cytokinetics CEO Robert Blum: An Interview With “The Pink Sheet” DAILY (Part 2 Of 2)
In the second part of the interview at the BIO Investor forum, CEO Robert Blum discusses Cytokinetics’ deal with Amgen and long-range commercialization goals.
Cytokinetics Plans Phase I/II Trial Of Ispinesib In First-Line Breast Cancer
Plan for the early stage program is announced simultaneously with disappointing outcomes from three mid-stage trials in various oncology settings.